The non-opioid pain patches market sale is expected to reach US$ 3.3 billion in sales by 2022. The market is anticipated to have expanded at a strong 4.1% CAGR and reach US$ 4.4 billion by 2029.
Major players in the market have recently shown interest in non-opioid pain patches due to the possibility for addiction and safety issues with alternative opioid pain treatments. In addition, non-addictive alternative medications are being promoted by governments and regulatory bodies to treat both acute and chronic pain.
In order to take advantage of this potential, major players in the non-opioid pain patch market are investing heavily in the research and development of innovative transdermal non-opioid pain technology. In the upcoming ten years, the market for non-opioid pain patches is anticipated to be driven by ongoing innovation in these innovative medications.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-11286
Key manufacturers operating in the market are offering a wide range of products such as lidocaine patches, diclofenac patches, methyl salicylate patches, capsaicin patches, ketoprofen patches, and others. Owing to the non-addictiveness of non-opioid pain therapeutics, there has been increasing demand for non-opioid pain patches, creating opportunity for the growth of the non-opioid pain patches market.
FMI – a well-established name in the market research domain – forecasts that, the non-opioid pain patches market will experience a major upturn post 2025, crossing the US$ 4 Billion mark by 2029.
That being said, the market is likely to witness decline in the near term due to the novel coronavirus (COVID-19) pandemic. The impact of the pandemic has been prominent in China, where the virus originated, and Europe – Spain, Italy, and France. Consequently, governments in these regions have imposed total lockdowns, leading to logistic nightmares, and gradual exhausting of existing non-opioid pain patches.
“Rising demand for safe and alternative chronic pain therapeutics, and supportive government policies, are anticipated to shape the future of long-term acting transdermal non-opioid analgesic patches.”
Key Takeaways:
- In terms of product type, the lidocaine patches segment is expected to capture over 65% of revenue share in the non-opioid pain patches market.
- Owing to superior topical effectiveness with minimal side-effects and prolonged transdermal drug release, lidocaine patches are the most preferred product type.
- In terms of distribution channel, hospital pharmacies and retail pharmacies & drug stores are expected to collectively hold over 70% of total value in the non-opioid pain patches market during the forecast period.
- North America is the highest revenue generating market by region, due to high R&D projects and conducive regulatory environment for non-opioid pain therapeutics. Europe is expected to offer lucrative opportunities, owing to the large aging population and increasing per capital healthcare expenditure.
Strategic Collaborations – Key Differentiating Strategy Followed by Leading Manufacturers
Leading manufacturers in the non-opioid pain patches market are focusing on external development collaboration to innovate novel therapeutics, in a bid to sustain market competition. For instance, in April 2021, Seattle-based Kineta Chronic Pain collaborated with Genentech to develop a non-opioid drug for the treatment of chronic pain. The underdevelopment drug is α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists, a novel target for the treatment of chronic neuropathic pain.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-11286
Non-opioid Pain Patches Market by Category
Product Type:
- Lidocaine Patches
- Diclofenac Patches
- Methyl Salicylate Patches
- Capsaicin Patches
- Ketoprofen Patches
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
